{
    "data": [
        {
            "id": 2984055,
            "title": "CBRE Grants Performance-Based Equity Award in Succession Plan",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>CBRE Group ( <a data-ticker=\"CBRE\" href=\"https://www.tipranks.com/stocks/cbre\">(CBRE)</a> ) has provided an update.</p>\n<p></p>\n<p></p><p>On February 25, 2026, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/cbre\" target=\"_blank\" ;=\"\" rel=\"nofollow\">CBRE Group</a></span>’s Compensation Committee granted a one-time, fully performance-based equity retention award with a $5 million target value to Chief Operating Officer and CEO of Advisory Services, Vikram Kohli, as part of the company’s long-term succession strategy. Structured entirely as performance-based restricted stock units split evenly between relative total shareholder return and relative earnings per share goals versus the S&amp;P 500, the award features a five-year vesting period, above-market performance hurdles starting at the 40th percentile, and potential payouts ranging from 0% to 175% of target, tying Kohli’s long-term compensation tightly to CBRE’s comparative shareholder returns and earnings growth.</p>\n<p>The award’s rTSR portion will measure cumulative total shareholder return from February 25, 2026, to January 31, 2031, while the rEPS portion will track Core EPS growth against peers’ GAAP EPS growth from January 1, 2026, to December 31, 2030, with vesting occurring after performance certification but no later than February 25, 2031. By extending vesting to five years and requiring performance above median for enhanced payouts, CBRE is signaling a strong commitment to rigorous pay-for-performance alignment, executive retention and competitive positioning in the S&amp;P 500 peer set, potentially reassuring investors about long-term leadership stability and disciplined incentive design.</p>\n<p>The most recent analyst rating on <a data-ticker=\"CBRE\" href=\"https://www.tipranks.com/stocks/cbre\">(CBRE)</a> stock is a Buy with a $180.00 price target. To see the full list of analyst forecasts on CBRE Group stock, see the CBRE <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/cbre/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>Spark’s Take on CBRE Stock</u></b></p>\n<p>According to Spark, TipRanks’ <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> Analyst, CBRE is a Neutral.</p>\n<p>The score is driven primarily by solid financial performance (notably a strengthened balance sheet and improving revenue trend) and upbeat earnings-call guidance for 2026 EPS growth. These positives are tempered by weak technical momentum (price below key moving averages with negative MACD) and a demanding valuation (P/E ~39.5 with no dividend support).</p>\n<p>To see Spark’s full report on CBRE stock, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/cbre/ai-stock-analysis\" target=\"_blank\" ;=\"\" rel=\"nofollow\">click here</a></span>. </p>\n<p><b><u>More about CBRE Group</u></b></p>\n<p>CBRE Group operates in the commercial real estate services and investment industry, providing advisory and transaction services, property management, and related financial and strategic consulting to corporate, institutional and investor clients globally. The company focuses on long-term value creation for shareholders through performance-based compensation structures that align executive incentives with market benchmarks and earnings growth.</p>\n<p><b>Average Trading Volume:</b> 1,921,999</p>\n<p><b>Technical Sentiment Signal:</b> Buy</p>\n<p><b>Current Market Cap:</b> $43.14B</p>\n<p></p>\n<p></p><p>For an in-depth examination of CBRE stock, go to <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/cbre\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Overview page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/shutterstock_1921507979-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/cbre-grants-performance-based-equity-award-in-succession-plan",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2026-02-27 06:50:03",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2984046,
            "title": "Morgan Stanley Direct Lending Posts Q4 Results, Declares Dividend",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>Morgan Stanley Direct Lending Fund ( <a data-ticker=\"MSDL\" href=\"https://www.tipranks.com/stocks/msdl\">(MSDL)</a> ) just unveiled an update.</p>\n<p></p>\n<p></p><p>On February 26, 2026, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/msdl\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Morgan Stanley Direct Lending Fund</a></span> reported fourth-quarter and full-year 2025 results, posting net investment income of $42.4 million, or $0.49 per share, slightly below the prior quarter’s $0.50 per share, with net asset value edging down to $20.26 and debt-to-equity rising to 1.20x. The board declared a first-quarter 2026 regular dividend of $0.45 per share and highlighted modest net deployment, a $3.8 billion predominantly first-lien debt portfolio, and the post-quarter launch of Capstone Lending LLC, a joint venture that expands its lending capacity alongside an institutional partner.</p>\n<p>For the quarter ended December 31, 2025, total investment income slipped to $96.6 million from $99.7 million, mainly due to lower base rates, while net expenses declined on a reduced incentive fee, and the company recorded unrealized depreciation and realized losses totaling $13.7 million. The launch of the Capstone Lending joint venture, supported by capital commitments of up to $200 million from the company and $50 million from its partner with nearly half initially called in February 2026, underscores a strategic move to scale origination and maintain its position in the competitive direct lending market while continuing to return capital through regular dividends.</p>\n<p>The most recent analyst rating on <a data-ticker=\"MSDL\" href=\"https://www.tipranks.com/stocks/msdl\">(MSDL)</a> stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Morgan Stanley Direct Lending Fund stock, see the MSDL <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/msdl/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>Spark’s Take on MSDL Stock</u></b></p>\n<p>According to Spark, TipRanks’ <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> Analyst, MSDL is a Neutral.</p>\n<p>The score is driven primarily by mixed financial performance: strong reported profitability is offset by weak cash flow quality and uncertainty in leverage trends. Valuation is a key positive with a low P/E and high dividend yield. Technicals are a drag due to a below-DMA downtrend and negative MACD, while the latest earnings call was moderately positive but flagged credit/NAV pressure via new nonaccruals and unrealized losses.</p>\n<p>To see Spark’s full report on MSDL stock, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/msdl/ai-stock-analysis\" target=\"_blank\" ;=\"\" rel=\"nofollow\">click here</a></span>. </p>\n<p><b><u>More about Morgan Stanley Direct Lending Fund</u></b></p>\n<p>Morgan Stanley Direct Lending Fund (NYSE: MSDL) is a publicly traded business development company externally managed by MS Capital Partners Adviser Inc. It focuses on direct lending, primarily through first-lien and other debt investments in middle-market companies across a diversified portfolio of 227 borrowers spanning 35 industries as of December 31, 2025.</p>\n<p><b>Average Trading Volume:</b> 844,749</p>\n<p><b>Technical Sentiment Signal:</b> Sell</p>\n<p><b>Current Market Cap:</b> $1.34B</p>\n<p></p>\n<p></p><p>Find detailed analytics on MSDL stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/msdl\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_212123620-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/morgan-stanley-direct-lending-posts-q4-results-declares-dividend",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2026-02-27 06:45:23",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2983990,
            "title": "Grupo Aval Publishes Q4 2025 Results Materials Ahead of Investor Call",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>Grupo Aval Acciones y Valores SA Pfd ( <a data-ticker=\"AVAL\" href=\"https://www.tipranks.com/stocks/aval\">(AVAL)</a> ) just unveiled an announcement.</p>\n<p></p>\n<p></p><p>On February 26, 2026, Grupo Aval Acciones y Valores S.A. announced that its materials for the quarterly consolidated results as of December 31, 2025, were made available to investors. The company noted that these documents support a results call scheduled for the same day, underscoring its ongoing disclosure practices and engagement with the international investment community.</p>\n<p>The release signals that Grupo Aval is maintaining its regular reporting cycle and providing detailed performance information to the market. This transparency is important for analysts and shareholders tracking the company’s financial position and strategic direction in the Latin American banking sector, although specific financial figures were not disclosed in the notice itself.</p>\n<p>The most recent analyst rating on <a data-ticker=\"AVAL\" href=\"https://www.tipranks.com/stocks/aval\">(AVAL)</a> stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Grupo Aval Acciones y Valores SA Pfd stock, see the AVAL <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/aval/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>Spark’s Take on AVAL Stock</u></b></p>\n<p>According to Spark, TipRanks’ <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> Analyst, AVAL is a Neutral.</p>\n<p>Overall score reflects a recovery in earnings and supportive earnings-call guidance, but is held back most by elevated leverage and weak cash flow conversion. Technicals are positive yet overextended, while valuation and dividend provide moderate support.</p>\n<p>To see Spark’s full report on AVAL stock, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/aval/ai-stock-analysis\" target=\"_blank\" ;=\"\" rel=\"nofollow\">click here</a></span>. </p>\n<p><b><u>More about Grupo Aval Acciones y Valores SA Pfd</u></b></p>\n<p>Grupo Aval Acciones y Valores S.A. is a Colombia-based financial holding company operating in the banking and financial services industry. Through its subsidiaries, it focuses on a broad range of retail and corporate banking, lending, and related financial products in Colombia and the wider Latin American market, targeting both local and international investors.</p>\n<p><b>Average Trading Volume:</b> 121,189</p>\n<p><b>Technical Sentiment Signal:</b> Buy</p>\n<p><b>Current Market Cap:</b> $5.24B</p>\n<p></p>\n<p></p><p>For a thorough assessment of AVAL stock, go to <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/aval\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2112464087-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/grupo-aval-publishes-q4-2025-results-materials-ahead-of-investor-call",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2026-02-27 06:31:22",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2983953,
            "title": "PPK Group Swings to Half-Year Profit on Nanomaterials Restructuring and Impairment Reversal",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>PPK Group Limited ( <a data-ticker=\"AU:PPK\" href=\"https://www.tipranks.com/stocks/au:ppk\">(AU:PPK)</a> ) has issued an update.</p>\n<p></p>\n<p></p><p>PPK Group Limited reported a sharp turnaround for the half-year to 31 December 2025, moving from a prior statutory loss to a profit of $10.5 million attributable to shareholders, supported by a 31% rise in revenue and a substantial swing in continuing operations back into the black. The result was heavily influenced by non-cash items, including a sizeable gain from the deconsolidation of White Graphene Ltd, a reversal of prior impairment on its Li-S Energy stake, and the reclassification of key nanomaterials holdings as associates, while the board opted against paying an interim dividend.</p>\n<p>Despite the headline profit, PPK’s underlying performance before tax remained loss-making, with the group posting an unaudited underlying pre-tax loss of $1.8 million once non-operating and non-cash impacts were stripped out. The restructuring of its portfolio, including the merger of White Graphene and BNNT Technology into a single nanomaterials business and reduced control over that asset, signals an ongoing shift toward an associate-investment model in advanced materials and energy storage, with implications for future earnings volatility and the balance between recurring operating returns and valuation-driven gains.</p>\n<p>The most recent analyst rating on <a data-ticker=\"AU:PPK\" href=\"https://www.tipranks.com/stocks/au:ppk\">(AU:PPK)</a> stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on PPK Group Limited stock, see the AU:PPK <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/au:ppk/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>More about PPK Group Limited</u></b></p>\n<p>PPK Group Limited is an Australian investment and technology company with interests spanning advanced materials, energy storage and commercialisation of innovative industrial technologies. The group has stakes in nanomaterials businesses such as White Graphene Ltd and BNNT Technology, as well as Li-S Energy, positioning it in emerging high-tech sectors with a focus on commercial applications.</p>\n<p><b>Average Trading Volume:</b> 37,768</p>\n<p><b>Technical Sentiment Signal:</b> Strong Sell</p>\n<p><b>Current Market Cap:</b> A$38.85M</p>\n<p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Industrials-2-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/ppk-group-swings-to-half-year-profit-on-nanomaterials-restructuring-and-impairment-reversal",
            "author": "TipRanks Australian Auto-Generated Newsdesk",
            "pub_date": "2026-02-27 06:26:22",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2983930,
            "title": "Gumtree Australia Swings to Half-Year Profit Despite Revenue Decline",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>The latest announcement is out from Market Herald Ltd ( <a data-ticker=\"AU:GUM\" href=\"https://www.tipranks.com/stocks/au:gum\">(AU:GUM)</a> ).</p>\n<p></p>\n<p></p><p>Gumtree Australia Markets Limited reported a 7 per cent decline in revenue from continuing operations and a 14 per cent fall in cash receipts for the half year to 31 December 2025, alongside an 8 per cent drop in operating cash flow. Despite softer top-line performance and cash generation, the company swung to a profit from continuing operations, with after-tax earnings of $813,056 compared with a loss a year earlier, and improved net intangible liabilities per share.</p>\n<p>The group did not declare a dividend for the period and recorded the loss of control of Subscribacar Pty Ltd on 22 October 2025, reflecting ongoing portfolio reshaping following the earlier sale of its Capital Markets business. The return to profitability, absence of realised and unrealised portfolio losses, and balance sheet improvements suggest a more streamlined operation, though reduced revenues and cash receipts highlight ongoing trading and demand challenges for stakeholders to monitor.</p>\n<p>The most recent analyst rating on <a data-ticker=\"AU:GUM\" href=\"https://www.tipranks.com/stocks/au:gum\">(AU:GUM)</a> stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Market Herald Ltd stock, see the AU:GUM <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/au:gum/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>More about Market Herald Ltd</u></b></p>\n<p>Gumtree Australia Markets Limited (ASX:GUM) operates an online marketplace platform in Australia, facilitating digital listings and transactions for consumers and businesses. Headquartered in Sydney, the company focuses on classified advertising and related services, positioning itself within the broader e-commerce and digital classifieds sector.</p>\n<p><b>Average Trading Volume:</b> 71,636</p>\n<p><b>Technical Sentiment Signal:</b> Strong Sell</p>\n<p><b>Current Market Cap:</b> A$38.52M</p>\n<p></p>\n<p></p><p>See more insights into GUM stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/au:gum\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Communication-Services-1-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/gumtree-australia-swings-to-half-year-profit-despite-revenue-decline",
            "author": "TipRanks Australian Auto-Generated Newsdesk",
            "pub_date": "2026-02-27 06:20:34",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2983833,
            "title": "Genesis Energy Raises Capital via Share Placement, Crown Stake Set at 51%",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>Genesis Energy Limited ( <a data-ticker=\"DE:1G6\" href=\"https://www.tipranks.com/stocks/de:1g6\">(DE:1G6)</a> ) has shared an update.</p>\n<p></p>\n<p></p><p>Genesis Energy Limited, the NZX-listed electricity and gas utility, has strengthened its capital base with a new equity issue while maintaining majority government ownership. The company continues to focus on a broad mix of institutional and retail investors to support a stable and engaged share register.</p>\n<p>Genesis has issued 46,511,627 new ordinary shares at NZ$2.15 each, raising cash and increasing its total shares on issue to 1,156,063,464, excluding treasury stock. The placement, conducted under NZX Listing Rule 4.5.1, ensured the Crown’s shareholding was set at 51.00% and allocated stock to selected existing shareholders and institutional investors, with decisions guided by pro rata considerations, long-term support, and advice from lead manager Jarden.</p>\n<p><b><u>More about Genesis Energy Limited</u></b></p>\n<p>Genesis Energy Limited is a New Zealand-based electricity and gas retailer and generator, listed on the NZX under ticker GNE. The company operates a portfolio of generation assets and serves residential, commercial, and industrial customers, with the New Zealand government (the Crown) as its controlling shareholder.</p>\n<p></p>\n<p></p><p>Learn more about 1G6 stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/de:1g6\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1933377149-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/genesis-energy-raises-capital-via-share-placement-crown-stake-set-at-51",
            "author": "TipRanks Australian Auto-Generated Newsdesk",
            "pub_date": "2026-02-27 06:05:22",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2983777,
            "title": "Neurogene Gains FDA Breakthrough Status for Rett Gene Therapy",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>Neurogene ( <a data-ticker=\"NGNE\" href=\"https://www.tipranks.com/stocks/ngne\">(NGNE)</a> ) has issued an update.</p>\n<p></p>\n<p></p><p>On February 26, 2026, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/ngne\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Neurogene</a></span> announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to NGN-401, its late-stage investigational AAV9 gene therapy for Rett syndrome. The decision was based on interim Phase 1/2 data through October 30, 2025, showing clinically meaningful, durable and multidomain functional improvements with continued skill acquisition, and a generally well-tolerated safety profile at the 1E15 vg dose.</p>\n<p>NGN-401, which uniquely delivers the full-length human MECP2 gene using Neurogene’s EXACT transgene regulation technology via intracerebroventricular administration, is being studied in the Embolden registrational trial, where dosing is expected to be completed in the second quarter of 2026. The new designation adds to a suite of U.S., European and U.K. regulatory recognitions and is poised to expedite development and review, potentially strengthening Neurogene’s competitive position in Rett syndrome therapies and offering stakeholders a clearer regulatory path toward possible approval.\n</p>\n<p>The most recent analyst rating on <a data-ticker=\"NGNE\" href=\"https://www.tipranks.com/stocks/ngne\">(NGNE)</a> stock is a Hold with a $19.50 price target. To see the full list of analyst forecasts on Neurogene stock, see the NGNE <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/ngne/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>Spark’s Take on NGNE Stock</u></b></p>\n<p>According to Spark, TipRanks’ <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> Analyst, NGNE is a Neutral.</p>\n<p>The score is held down primarily by weak financial performance (no TTM revenue, widening losses, and sizable cash burn) and bearish technicals (trading below key moving averages with negative MACD). These are partially offset by a strong balance sheet and positive clinical/regulatory progress in NGN-401 that supports the longer-term thesis but does not yet reduce near-term execution and funding risk.</p>\n<p>To see Spark’s full report on NGNE stock, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/ngne/ai-stock-analysis\" target=\"_blank\" ;=\"\" rel=\"nofollow\">click here</a></span>. </p>\n<p><b><u>More about Neurogene</u></b></p>\n<p>Neurogene Inc. is a clinical-stage biotechnology company focused on developing life-changing genetic medicines for patients and families affected by rare and devastating neurological diseases. The Nasdaq-listed company is advancing purpose-built gene therapies powered by its proprietary EXACT transgene regulation technology, with lead program NGN-401 positioned as a potential best-in-class, one-time treatment for Rett syndrome.</p>\n<p>The company employs a biology-first approach combined with optimized delivery methods, including intracerebroventricular administration, to broadly target the brain and nervous system. Neurogene’s regulatory strategy has yielded multiple U.S. and international designations for NGN-401, underscoring its ambition to establish a strong foothold in the rare neurogenetic disease market.</p>\n<p><b>Average Trading Volume:</b> 153,744</p>\n<p><b>Technical Sentiment Signal:</b> Strong Sell</p>\n<p><b>Current Market Cap:</b> $292.8M</p>\n<p></p>\n<p></p><p>Learn more about NGNE stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/ngne\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1911898180-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/neurogene-gains-fda-breakthrough-status-for-rett-gene-therapy",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2026-02-27 05:56:03",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2983710,
            "title": "Targa Resources Prices $1.5 Billion Senior Notes Offering",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>An update from Targa Resources ( <a data-ticker=\"TRGP\" href=\"https://www.tipranks.com/stocks/trgp\">(TRGP)</a> ) is now available.</p>\n<p></p>\n<p></p><p>On February 25, 2026, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/trgp\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Targa Resources</a></span> Corp. priced an underwritten public offering of $1.5 billion in senior notes, split evenly between 4.350% notes due 2031 and 6.050% notes due 2056, with the securities sold slightly below face value. The notes, fully and unconditionally guaranteed on a senior unsecured basis by certain subsidiaries, are expected to close on March 2, 2026, with interest accruing from that date and payable semi-annually.</p>\n<p>Targa plans to use the net proceeds for general corporate purposes, including repaying commercial paper and other indebtedness, repurchasing or redeeming securities, and funding capital expenditures, working capital and subsidiary investments. The offering, conducted under an effective shelf registration and supported by major underwriting banks that also have lending and derivatives relationships with Targa, is set to bolster the company’s financial flexibility and balance sheet management as it continues to invest in its midstream infrastructure portfolio.\n</p>\n<p>The most recent analyst rating on <a data-ticker=\"TRGP\" href=\"https://www.tipranks.com/stocks/trgp\">(TRGP)</a> stock is a Buy with a $262.00 price target. To see the full list of analyst forecasts on Targa Resources stock, see the TRGP <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/trgp/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>Spark’s Take on TRGP Stock</u></b></p>\n<p>According to Spark, TipRanks’ <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> Analyst, TRGP is a Neutral.</p>\n<p>The score is driven primarily by strong operational/earnings momentum and a positive forward outlook (EBITDA growth guidance, expanding Permian footprint, and mostly fee-based/hedged cash flows). Offsetting this are meaningful leverage risk on the balance sheet, technically overbought signals that raise near-term pullback risk, and a relatively high P/E with only a modest dividend yield.</p>\n<p>To see Spark’s full report on TRGP stock, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/trgp/ai-stock-analysis\" target=\"_blank\" ;=\"\" rel=\"nofollow\">click here</a></span>. </p>\n<p><b><u>More about Targa Resources</u></b></p>\n<p>Targa Resources Corp. is a leading U.S. midstream services provider and one of the largest independent energy infrastructure companies in North America. The company owns, operates, acquires and develops a diversified portfolio of domestic assets that connect natural gas and natural gas liquids to domestic and international markets with growing demand for cleaner fuels and feedstocks.</p>\n<p>Its operations are positioned as critical infrastructure for the efficient, safe and reliable delivery of energy across the United States and increasingly to global customers. This focus on connecting natural gas and NGL supply to end markets underpins Targa’s role in the energy value chain and supports its growth strategy in midstream infrastructure.\n</p>\n<p><b>Average Trading Volume:</b> 1,411,153</p>\n<p><b>Technical Sentiment Signal:</b> Buy</p>\n<p><b>Current Market Cap:</b> $49.81B</p>\n<p></p>\n<p></p><p>Find detailed analytics on TRGP stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/trgp\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2023/06/Energy-7-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/targa-resources-prices-1-5-billion-senior-notes-offering",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2026-02-27 05:45:22",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2983656,
            "title": "Castle Biosciences Posts Modest 2025 Growth Amid Headwinds",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>Castle Biosciences ( <a data-ticker=\"CSTL\" href=\"https://www.tipranks.com/stocks/cstl\">(CSTL)</a> ) has provided an update.</p>\n<p></p>\n<p></p><p>On Feb. 26, 2026, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/cstl\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Castle Biosciences</a></span> reported fourth-quarter and full-year 2025 results, posting 2025 revenue of $344.2 million, up 4% year over year and above guidance, with core tests DecisionDx-Melanoma and TissueCypher driving a 37% increase in total test reports. Overall growth was tempered by Medicare coverage changes for DecisionDx-SCC and the May 2025 discontinuation of IDgenetix, contributing to a shift from 2024 net income to a 2025 net loss of $24.2 million, even as the company generated $64.3 million in operating cash flow and ended the year with $299.5 million in cash and investments.</p>\n<p>Fourth-quarter 2025 revenue rose 1% to $87.0 million, with core test volumes up 42%, but the company moved from prior-year quarterly profit to a small net loss as Adjusted EBITDA declined to $11.5 million. During late 2025, Castle bolstered its clinical and market positioning with new consensus and clinical data supporting DecisionDx-Melanoma, a meta-analysis validating TissueCypher’s risk-stratification performance, and the limited access launch of AdvanceAD-Tx, while guiding for 2026 revenue in the $340–350 million range, signaling continued focus on high-growth, high-evidence franchises despite reimbursement headwinds and portfolio pruning.</p>\n<p>The most recent analyst rating on <a data-ticker=\"CSTL\" href=\"https://www.tipranks.com/stocks/cstl\">(CSTL)</a> stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Castle Biosciences stock, see the CSTL <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/cstl/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>Spark’s Take on CSTL Stock</u></b></p>\n<p>According to Spark, TipRanks’ <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> Analyst, CSTL is a Neutral.</p>\n<p>The score is anchored by mixed financial performance (profitability and free-cash-flow growth concerns) but supported by constructive technicals and clear operating momentum from raised guidance, strong test volume growth, and new product launch traction. Valuation remains a key drawback due to losses (negative P/E) and no dividend support, while reimbursement uncertainty is an important ongoing risk.</p>\n<p>To see Spark’s full report on CSTL stock, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/cstl/ai-stock-analysis\" target=\"_blank\" ;=\"\" rel=\"nofollow\">click here</a></span>. </p>\n<p><b><u>More about Castle Biosciences</u></b></p>\n<p>Castle Biosciences, Inc., based in Friendswood, Texas, operates in the molecular diagnostics and precision medicine industry, developing gene expression profile and tissue-based tests that guide patient care. Its core portfolio targets dermatologic and gastrointestinal diseases, led by DecisionDx-Melanoma for cutaneous melanoma and TissueCypher for Barrett’s esophagus, with an expanding presence in dermatology through offerings such as the newly launched AdvanceAD-Tx test for atopic dermatitis.</p>\n<p><b>Average Trading Volume:</b> 389,093</p>\n<p><b>Technical Sentiment Signal:</b> Buy</p>\n<p><b>Current Market Cap:</b> $873.9M</p>\n<p></p>\n<p></p><p>For a thorough assessment of CSTL stock, go to <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/cstl\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1917115745-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/castle-biosciences-posts-modest-2025-growth-amid-headwinds",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2026-02-27 05:36:20",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        },
        {
            "id": 2983622,
            "title": "Moolec Science Overhauls Board With New Quality-Focused Director",
            "description": "<html><head></head><body><p></p><p></p><h3 style=\"text-decoration: underline; text-decoration-color: #1e77f9;\"><a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\">Claim 50% Off TipRanks Premium</a></h3><ul style=\"padding-top: 5px;\"><li>Unlock <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> hedge fund-level data </a> and <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> powerful investing tools </a> for smarter, sharper decisions \n</li><li> Stay ahead of the market with <a data-link=\"article_promo\" href=\"https://www.tipranks.com/checkout/v2?subscription=tipranks-premium-yearly&amp;llf=rss&amp;coupon=INTRO50P&amp;checkoutPage=checkoutv2\"> the latest news and analysis </a> and maximize your portfolio's potential</li></ul><p></p><p>Moolec Science ( <a data-ticker=\"MLEC\" href=\"https://www.tipranks.com/stocks/mlec\">(MLEC)</a> ) has issued an announcement.</p>\n<p></p>\n<p></p><p>On February 25, 2025, Moolec Science SA, a plant- and microbe-based protein innovator for the global food industry, announced a reshaping of its board of directors. The company appointed U.S.-based quality and operations veteran Daniel Core to its board, adding him to both the audit and compensation committees to bolster governance, compliance oversight, and operational risk management.</p>\n<p>Effective the same day, directors Aimar Dimo and Gloria Montaron Estrada resigned from the board, marking a notable refresh of Moolec’s governance structure. The changes signal an increased emphasis on industrial-quality discipline and regulatory frameworks as the company advances its technology-driven, seed-to-ingredient strategy across its key markets in the United States, Europe, and South America.</p>\n<p>The most recent analyst rating on <a data-ticker=\"MLEC\" href=\"https://www.tipranks.com/stocks/mlec\">(MLEC)</a> stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Moolec Science stock, see the MLEC <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/mlec/forecast\" target=\"_blank\" ;=\"\" rel=\"nofollow\">Stock Forecast page</a></span>.</p>\n<p><b><u>Spark’s Take on MLEC Stock</u></b></p>\n<p>According to Spark, TipRanks’ <a data-autolink=\"true\" href=\"https://www.tipranks.com/compare-stocks/artificial-intelligence\">AI</a> Analyst, MLEC is a Neutral.</p>\n<p>The score is held back primarily by weak financial fundamentals—large losses, negative free cash flow, and a materially stressed balance sheet with negative equity and higher debt. Technicals are a partial offset with strong momentum and price above key moving averages, though the very high RSI indicates an overextended setup. Valuation is also constrained by negative earnings and no dividend support.</p>\n<p>To see Spark’s full report on MLEC stock, <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/mlec/ai-stock-analysis\" target=\"_blank\" ;=\"\" rel=\"nofollow\">click here</a></span>. </p>\n<p><b><u>More about Moolec Science</u></b></p>\n<p>Moolec Science SA is a Nasdaq-listed food technology company that engineers plants and microbes to produce scalable protein solutions for the global food system. Combining Molecular Farming with precision fermentation, it develops alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture, supported by a portfolio of more than 52 granted and pending patents.</p>\n<p><b>Average Trading Volume:</b> 1,379,712</p>\n<p><b>Technical Sentiment Signal:</b> Sell</p>\n<p><b>Current Market Cap:</b> $11.41M</p>\n<p></p>\n<p></p><p>See more data about MLEC stock on <span class=\"tr-stock-ticker\" style=\"color:blue\"><a href=\"https://www.tipranks.com/stocks/mlec\" target=\"_blank\" ;=\"\" rel=\"nofollow\">TipRanks’ Stock Analysis page</a></span>.</p><p></p>",
            "image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1423187486-750x406.jpg",
            "link": "https://www.tipranks.com/news/company-announcements/moolec-science-overhauls-board-with-new-quality-focused-director",
            "author": "TipRanks Auto-Generated Newsdesk",
            "pub_date": "2026-02-27 05:30:40",
            "source": "tipranks_announcements",
            "kind": 1,
            "language": "en"
        }
    ]
}